AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24521887 — intervention group
Group type: EXPERIMENTAL
Intervention: LACJ (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + jinghuaweikang gelatin pearls 240 mg, twice daily for 10 days, then jinghuaweikang gelatin pearls 240 mg, twice daily for 14 days)
Number of subjects: 90
Study 24521887 — intervention group
Group type: COMPARATOR
Intervention: LACB (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + bismuth potassium citrate 220 mg, twice daily for 10 days)
Number of subjects: 90
Study 21248360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐esophageal infusion of 5‐mL acidic solution (0.1 N HCl)
Number of subjects: 12
Study 21248360 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 18979719 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of perindopril and indapamide
Number of subjects: 0
Study 16984212 — intervention group
Group type: EXPERIMENTAL
Intervention: Traxoprodil 100mg oral dose
Number of subjects: 17
Study 16984212 — intervention group
Group type: EXPERIMENTAL
Intervention: Traxoprodil 50mg oral dose
Number of subjects: 17
Study 16984212 — intervention group
Group type: EXPERIMENTAL
Intervention: Traxoprodil 300mg oral dose
Number of subjects: 17
Study 16984212 — intervention group
Group type: EXPERIMENTAL
Intervention: Traxoprodil 50mg intravenous infusion
Number of subjects: 17
Study 16984212 — intervention group
Group type: EXPERIMENTAL
Intervention: Traxoprodil 100mg intravenous infusion
Number of subjects: 17
Study 16984212 — intervention group
Group type: EXPERIMENTAL
Intervention: Traxoprodil oral administration in poor metabolisers
Number of subjects: 17
Study 16984212 — intervention group
Group type: EXPERIMENTAL
Intervention: Traxoprodil oral administration in extensive metabolisers
Number of subjects: 17
Study 12683359 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal patients
Number of subjects: 3
Study 12683359 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior parietal patients
Number of subjects: 3
Study 12683359 — intervention group
Group type: COMPARATOR
Intervention: Non-brain-injured subjects (control)
Number of subjects: 3
Study 10969351 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 immunogen, Remune (inactivated, gp120‐depleted immunogen in IFA)
Number of subjects: 10
Study 8956766 — intervention group
Group type: COMPARATOR
Intervention: Control enteral formula (1 L/d for 7 days before surgery)
Number of subjects: 40
Study 8956766 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched enteral formula (1 L/d for 7 days before surgery, enriched with arginine, RNA, and omega-3 fatty acids)
Number of subjects: 40
Study 8005921 — intervention group
Group type: EXPERIMENTAL
Intervention: Guargum (20 grams)
Number of subjects: 50
Study 8005921 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 50
Study 8005921 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Guargum (10 grams) and Acarbose (50 grams)
Number of subjects: 50
Study 8005921 — intervention group
Group type: COMPARATOR
Intervention: Control (without trial drugs)
Number of subjects: 50
Study 10284954 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-bed geriatric units with individualized interventions and multidisciplinary approach
Number of subjects: 0
Study 28980870 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol
Number of subjects: 60
Study 28980870 — intervention group
Group type: COMPARATOR
Intervention: metformin
Number of subjects: 60
Study 27717336 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding (first feeding bolus with a polymeric diet (1 kcal/ml) via a feeding tube 3 hours after PEG placement)
Number of subjects: 0
Study 27717336 — intervention group
Group type: COMPARATOR
Intervention: Late enteral feeding (first feeding bolus 8 hours after PEG placement)
Number of subjects: 0
Study 27717336 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Number of subjects: 0
Study 27717336 — intervention group
Group type: COMPARATOR
Intervention: Late enteral feeding
Number of subjects: 0
Study 26263079 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site myomectomy (LESS-M)
Number of subjects: 100
Study 26263079 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic myomectomy (LM)
Number of subjects: 100
Study 23439892 — intervention group
Group type: EXPERIMENTAL
Intervention: Child manikin model
Number of subjects: 45
Study 23439892 — intervention group
Group type: COMPARATOR
Intervention: Adult manikin model
Number of subjects: 45
Study 22051490 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated brackets (group A)
Number of subjects: 12
Study 22051490 — intervention group
Group type: COMPARATOR
Intervention: Adhesive precoated brackets (group B)
Number of subjects: 12
Study 19168190 — intervention group
Group type: COMPARATOR
Intervention: Stable group
Number of subjects: 181
Study 19168190 — intervention group
Group type: EXPERIMENTAL
Intervention: Reached Confirmed Sustained Progression (RCSP) group
Number of subjects: 181
Study 19168190 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 181
Study 16536766 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil 50 mg for 4 weeks
Number of subjects: 34
Study 16536766 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg for 4 weeks
Number of subjects: 34
Study 14642684 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day for 8 weeks followed by 8 mg/day for 4 weeks)
Number of subjects: 84
Study 11104336 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 11104336 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular techniques (stent‐supported angioplasty)
Number of subjects: 0
Study 9436940 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) combined with chemotherapy
Number of subjects: 2286
Study 9436940 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 2286
Study 9436940 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN maintenance therapy
Number of subjects: 2286
Study 8437779 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg aspirin daily
Number of subjects: 14
Study 8437779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8437779 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnant women (control group)
Number of subjects: 14
Study 3676158 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Fe
Number of subjects: 0
Study 3676158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30033619 — intervention group
Group type: EXPERIMENTAL
Intervention: FAB 10 (esomeprazole 20 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days)
Number of subjects: 0
Study 30033619 — intervention group
Group type: EXPERIMENTAL
Intervention: FAB 7 (same as FAB 10 but for 7 days)
Number of subjects: 0
Study 30033619 — intervention group
Group type: EXPERIMENTAL
Intervention: FA 10 (esomeprazole 20 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days, without bismuth)
Number of subjects: 0
Study 30033619 — intervention group
Group type: EXPERIMENTAL
Intervention: FA 7 (same as FA 10 but for 7 days)
Number of subjects: 0
Study 30033619 — intervention group
Group type: EXPERIMENTAL
Intervention: FAB 10
Number of subjects: 0
Study 30033619 — intervention group
Group type: EXPERIMENTAL
Intervention: FAB 7
Number of subjects: 0
Study 30033619 — intervention group
Group type: EXPERIMENTAL
Intervention: FA 10
Number of subjects: 0
Study 30033619 — intervention group
Group type: EXPERIMENTAL
Intervention: FA 7
Number of subjects: 0
Study 30033619 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 0
Study 27089872 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved latrines
Number of subjects: 1200
Study 27089872 — intervention group
Group type: COMPARATOR
Intervention: Improved water and sanitation (after the second phase)
Number of subjects: 1200
Study 27089872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitation Calendar recording by mothers or caregivers
Number of subjects: 1200
Study 23184061 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR(BC)
Number of subjects: 82
Study 23184061 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 82
Study 22490404 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antithrombotic therapy for two weeks
Number of subjects: 40
Study 20602497 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative magnesium hydroxide as a laxative
Number of subjects: 74
Study 20602497 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 74
Study 20602497 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of laxative and ONS
Number of subjects: 74
Study 20602497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 74
Study 20602497 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 74
Study 18523415 — intervention group
Group type: EXPERIMENTAL
Intervention: DM‐o 0.25%
Number of subjects: 0
Study 18523415 — intervention group
Group type: EXPERIMENTAL
Intervention: DM‐fo 0.25%
Number of subjects: 0
Study 18523415 — intervention group
Group type: EXPERIMENTAL
Intervention: BM 0.05%
Number of subjects: 0
Study 18523415 — intervention group
Group type: EXPERIMENTAL
Intervention: CP 0.05%
Number of subjects: 0
Study 18523415 — intervention group
Group type: EXPERIMENTAL
Intervention: HC 1.0%
Number of subjects: 0
Study 18523415 — intervention group
Group type: EXPERIMENTAL
Intervention: DM vehicles
Number of subjects: 0
Study 15860070 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering in-service training program for foreign nurse aides (3-month duration)
Number of subjects: 35
Study 12912783 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-glycemic load diet
Number of subjects: 16
Study 12912783 — intervention group
Group type: COMPARATOR
Intervention: Reduced-fat diet
Number of subjects: 16
Study 10533765 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 269
Study 10533765 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime/metronidazole
Number of subjects: 269
Study 8978112 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk reduction presentation
Number of subjects: 73
Study 8978112 — intervention group
Group type: COMPARATOR
Intervention: Other presentations (absolute risk reduction, difference in event-free patients, number needed to treat)
Number of subjects: 73
Study 8978112 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatment preferences
Number of subjects: 73
Study 8978112 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of statistics
Number of subjects: 73
Study 1590013 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) evaluation of stone density prior to ESWL
Number of subjects: 97
Study 1590013 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 97
Study 4017670 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of 100-proof vodka per kg of body weight in orange juice
Number of subjects: 18
Study 4017670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29804794 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with pasteurized raw egg white
Number of subjects: 0
Study 29804794 — intervention group
Group type: COMPARATOR
Intervention: Cooked egg white
Number of subjects: 0
Study 29804794 — intervention group
Group type: COMPARATOR
Intervention: Pasteurized raw egg white
Number of subjects: 0
Study 29804794 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE specific of ovomucoid titer <2.045kU/l
Number of subjects: 0
Study 26774322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented ISPs with an abutment screw access hole (study group)
Number of subjects: 393
Study 26774322 — intervention group
Group type: COMPARATOR
Intervention: Conventional cemented ISPs without access hole (control group)
Number of subjects: 393
Study 24863631 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-20 ml/kg FFP (FFP group, n=50)
Number of subjects: 100
Study 24863631 — intervention group
Group type: COMPARATOR
Intervention: 10-20 ml/kg 4% succinylated gelatin (Gelofusine, GEL group, n=50)
Number of subjects: 100
Study 22207015 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline for initiation and maintenance of insulin infusions for hyperglycemia
Number of subjects: 0
Study 20108171 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery
Number of subjects: 92
Study 20108171 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 92
Study 18378918 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous retransfusion drains
Number of subjects: 178
Study 18378918 — intervention group
Group type: COMPARATOR
Intervention: Standard care with vacuum drain (Control)
Number of subjects: 178
Study 18378918 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 178
Study 15948160 — intervention group
Group type: EXPERIMENTAL
Intervention: RT directly after BCS
Number of subjects: 1831
Study 15948160 — intervention group
Group type: EXPERIMENTAL
Intervention: RT after the third chemotherapy cycle
Number of subjects: 1831
Study 15948160 — intervention group
Group type: EXPERIMENTAL
Intervention: RT after the sixth chemotherapy cycle
Number of subjects: 1831
Study 15948160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 1831
Study 15948160 — intervention group
Group type: COMPARATOR
Intervention: 1-3 chemotherapy cycles
Number of subjects: 1831
Study 11926969 — intervention group
Group type: EXPERIMENTAL
Intervention: DBP-Estimated dp/dt
Number of subjects: 36
Study 11926969 — intervention group
Group type: COMPARATOR
Intervention: Doppler-derived dp/dt
Number of subjects: 36
Study 11926969 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between DBP-Estimated and Doppler-derived dp/dt
Number of subjects: 36
Study 10609711 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented measurement of total AP displacement during loading to 125 N of AP force
Number of subjects: 41
Study 10609711 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented measurement of total I-E rotation during loading to 4000 N-mm torque
Number of subjects: 41
Study 8955656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane (10:1 dose ratio with epirubicin)
Number of subjects: 162
Study 8955656 — intervention group
Group type: COMPARATOR
Intervention: Control (epirubicin without dexrazoxane)
Number of subjects: 162
Study 2008281 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% prodrug
Number of subjects: 66
Study 2008281 — intervention group
Group type: COMPARATOR
Intervention: 10% viscous phenylephrine hydrochloride (HCl)
Number of subjects: 66
Study 6662683 — intervention group
Group type: EXPERIMENTAL
Intervention: azlocillin-gentamicin (AZ-G)
Number of subjects: 58
Study 6662683 — intervention group
Group type: COMPARATOR
Intervention: ampicillin-gentamicin (AM-G)
Number of subjects: 58
Study 31654944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid comprehensive telerehabilitation (TR) + usual care
Number of subjects: 850
Study 31654944 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 850
Study 29327180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT)
Number of subjects: 13004
Study 29327180 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (CT)
Number of subjects: 13004
Study 26888417 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina supplementation (3 g/day)
Number of subjects: 0
Study 25195522 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (dGTE)
Number of subjects: 19
Study 25195522 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 19
Study 22698766 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic canola oil (HOCO) diet
Number of subjects: 34
Study 22698766 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FXCO) diet
Number of subjects: 34
Study 22698766 — intervention group
Group type: COMPARATOR
Intervention: Typical Western diet (WD)
Number of subjects: 34
Study 20487234 — intervention group
Group type: EXPERIMENTAL
Intervention: IIEF-15 questionnaire
Number of subjects: 137
Study 17509103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 mcg/day
Number of subjects: 129
Study 17509103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 48 mcg/day
Number of subjects: 129
Study 17509103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 72 mcg/day
Number of subjects: 129
Study 17509103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 16307962 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone 3 mg and ethinyl estradiol (EE) 20 mcg
Number of subjects: 64
Study 16307962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 12088811 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil
Number of subjects: 100
Study 12088811 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 100
Study 9701720 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 times daily for 6 days)
Number of subjects: 36
Study 9701720 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (acute ingestion)
Number of subjects: 36
Study 9701720 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (chronic exposure)
Number of subjects: 36
Study 9701720 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine withdrawal
Number of subjects: 36
Study 9701720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7649960 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 16
Study 7649960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2539180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir 5 mg kg‐1 t.d.s. for 23 days followed by oral acyclovir 800 mg 6‐hourly for 6 months
Number of subjects: 82
Study 2539180 — intervention group
Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 82
Study 2539180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir and oral acyclovir
Number of subjects: 82
Study 773085 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B lozenges
Number of subjects: 100
Study 773085 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine denture immersion
Number of subjects: 100
Study 773085 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 100
Study 773085 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine sucking
Number of subjects: 100
Study 773085 — intervention group
Group type: COMPARATOR
Intervention: Water denture soaking
Number of subjects: 100
Study 31481110 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated smoking cessation clinic
Number of subjects: 450
Study 31481110 — intervention group
Group type: COMPARATOR
Intervention: Standard care with ultrasound screening for fetal growth restriction
Number of subjects: 450
Study 31481110 — intervention group
Group type: COMPARATOR
Intervention: Standard care with ultrasound screening for growth restriction only if clinically indicated
Number of subjects: 450
Study 28120017 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal sciatic nerve block (DSB) out-of-plane with 30 ml of Mepivacaine 1%
Number of subjects: 56
Study 28120017 — intervention group
Group type: COMPARATOR
Intervention: Proximal sciatic nerve block (DSB) in-plane with 30 ml of Mepivacaine 1%
Number of subjects: 56
Study 26545677 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week resistance circuit training programme, 3-days per week
Number of subjects: 48
Study 26545677 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 23159875 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg transdermal nicotine
Number of subjects: 26
Study 23159875 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral mecamylamine
Number of subjects: 26
Study 23159875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21112719 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Programme (CDSMP)
Number of subjects: 0
Study 18801802 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion and standard oxygenator (Group 2)
Number of subjects: 40
Study 18801802 — intervention group
Group type: COMPARATOR
Intervention: No transfusion and coated oxygenator (Group 3)
Number of subjects: 40
Study 18801802 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion and coated oxygenator (Group 4)
Number of subjects: 40
Study 18801802 — intervention group
Group type: COMPARATOR
Intervention: No transfusion and standard oxygenator (Group 1)
Number of subjects: 40
Study 17083268 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 100
Study 17083268 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 100
Study 17083268 — intervention group
Group type: COMPARATOR
Intervention: Normotensive healthy volunteers
Number of subjects: 100
Study 15554351 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment
Number of subjects: 33
Study 15554351 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 healthy female subjects)
Number of subjects: 33
Study 11414530 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol aerosol via Jet nebulizer
Number of subjects: 53
Study 11414530 — intervention group
Group type: COMPARATOR
Intervention: Albuterol aerosol via MDI-spacer
Number of subjects: 53
Study 9209217 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized tutorial on the vallecula sign
Number of subjects: 52
Study 8136620 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (HI)
Number of subjects: 10
Study 8136620 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin (PI)
Number of subjects: 10
Study 2443539 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg prednisone per day for 2 days before challenge
Number of subjects: 13
Study 2443539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13